HomeNews

News

Betuvax coronavirus vaccine clinical trials to begin in September

The Betuvax-CoV-2 is a split recombinant vaccine of the basis of spherical particles with the coronavirus surface antigen (protein).

Coronavirus mutations only slightly reduce vaccines’ efficacy

The mutations of the novel coronavirus cause only a marginal decrease in the efficacy of vaccines certified in Russia.

The combination between the AstraZeneca vaccine and the Sputnik Light shows no serious adverse events

In August 2021, RDIF and partners will publish initial data on the immunogenicity of the combined use of the AstraZeneca vaccine and the Sputnik V vaccine in Azerbaijan.

Uzbekistan produces first batch of Sputnik V vaccine

At the first stage, the vaccine will be produced using raw materials from Russia, in the future a full cycle of production from local components.

Delta strain may become standard for coronavirus vaccines, expert says

When developing new vaccines in the future, the basis of vaccines registered in Russia will probably be replaced with the Delta variant.

Contract production of pharmaceutical ingredients by 2028 may reach $ 136 billion

The traditional active pharmaceutical ingredient dominated the market and accounted for the largest revenue share of 40.5% in 2020.
spot_img

Expert Articles

spot_img